| PIK3CA as an oncogene in cervical cancer. | cervical, |
| Involvement of PI3K in PKCepsilon-mediated oncogenic signal in rat colonic epithelial cells. | colorectal, |
| The oncogene phosphatidylinositol 3 -kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma. | ovarian, |
| Data indicate that mutations of PIK3CA play an oncogenic role in substantial fractions of ovarian and breast carcinomas. | breast,ovarian, |
| Mutant PIK3CA is likely to function as an oncogene in anaplastic thyroid cancer and less frequently well-differentiated thyroid carcinomas. | thyroid, |
| Mutation of the PIK3CA gene in anaplastic thyroid cancer. | thyroid, |
| First report of PIK3CA mutation in pancreatic cancer, providing evidence of its oncogenic properties. | pancreatic, |
| PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma. | oral |
| These results suggest that there is a fine distinction between the signaling activators and downstream effectors of the oncogenic PI3K and RAS pathways in breast epithelium and those in other tissues. | breast, |
| Genetic and pharmacologic evidence implicating the p85 alpha, but not p85 beta, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis. | leukemia, |
| oncogenic PIK3CA mutations contribute to the pathogenesis of skin tumors lacking malignant potential | skin, |
| PIK3CA mutations in HNSCC are likely to be oncogenic and may significantly contribute to HNSCC carcinogenesis and pave attractive target for therapeutic prevention. | HNSC, |
| Transcriptional regulation of PIK3CA oncogene by NF-kappaB in ovarian cancer microenvironment. | ovarian, |
| Oncogenic NOTCH1 control of MYC and PI3K: challenges and opportunities for anti-NOTCH1 therapy in T-cell acute lymphoblastic leukemias and lymphomas. | lymphoma,leukemia, |
| BRAF, KRAS and PIK3CA mutations occur prior to malignant transformation demonstrating that these oncogenic alterations are primary genetic events in colorectal carcinogenesis | colorectal, |
| Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. | endometrial, |
| In the current study of primary uterine serous carcinoma (USC) tumors, oncogenic mutations of the PIK3CA gene were seen in 15% of USC cases | uterine, |
| Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo. | thyroid, |
| Oncogenic mutation of PIK3CA in small cell lung carcinoma: a potential therapeutic target pathway for chemotherapy-resistant lung cancer. | lung, |
| Phosphatidylinositol 3-kinase (PI3K) signaling pathway occurs frequently in human cancer; PTEN tumor suppressor or PIK3CA oncogene mutations both direct PI3K-dependent tumorigenesis in breast cancers | breast, |